Glucagon receptor antagonist-3
Based on 1 Customer Validation
Glucagon receptor antagonist-3 is a glucagon receptor antagonist. Glucagon receptor antagonist-3 can be used for research on type 2 diabetes.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.78%
- CAS. Nr.: 202917-17-7
- Formel: C22H30FNO2
- Molecular Weight:359.48
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-50663
MK 0893GCGR Antagonist -
HY-50158
Glucagon receptor antagonist-2Glucagon Receptor Antagonist -
HY-103547
L-168049Glucagon Receptor Antagonist -
HY-124622
NNC-0640GCGR Modulator -
HY-P0264
Exendin(9-39) amideGLP-1R Antagonist -
HY-13443
Exendin-4GLP-1 Receptor Agonist -
HY-103546
BETPGLP-1 Agonist -
HY-114118
SemaglutideGLP-1R Agonist -
HY-P0014
LiraglutideGLP-1R Agonist -
HY-12525
LGD-6972 -
HY-P0054A
GLP-1(7-36), amideGCGR Agonist -
HY-114118CP
Semaglutide (crude)Crude Semaglutide
Biologische Aktivität
Beschreibung
In Vitro
Glucagon receptor antagonist-3 is a structural analog of glucagon receptor antagonist compound 4a in the text[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS. Nr. 202917-17-7
-
Appearance Solid
-
Molecular Weight 359.48
-
Formel C22H30FNO2
-
Color White to off-white
-
SMILES
CC(C1=NC(C(C)C)=C([C@]([C@]2=CC=C(C=C2O)F)=C1[C@@H](C)O)CCC)C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 100 mg/mL (278.18 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3 mg/mL (8.35 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7818 mL | 13.9090 mL | 27.8180 mL | 69.5449 mL |
| 5 mM | 0.5564 mL | 2.7818 mL | 5.5636 mL | 13.9090 mL | |
| 10 mM | 0.2782 mL | 1.3909 mL | 2.7818 mL | 6.9545 mL | |
| 15 mM | 0.1855 mL | 0.9273 mL | 1.8545 mL | 4.6363 mL | |
| 20 mM | 0.1391 mL | 0.6954 mL | 1.3909 mL | 3.4772 mL | |
| 25 mM | 0.1113 mL | 0.5564 mL | 1.1127 mL | 2.7818 mL | |
| 30 mM | 0.0927 mL | 0.4636 mL | 0.9273 mL | 2.3182 mL | |
| 40 mM | 0.0695 mL | 0.3477 mL | 0.6954 mL | 1.7386 mL | |
| 50 mM | 0.0556 mL | 0.2782 mL | 0.5564 mL | 1.3909 mL | |
| 60 mM | 0.0464 mL | 0.2318 mL | 0.4636 mL | 1.1591 mL | |
| 80 mM | 0.0348 mL | 0.1739 mL | 0.3477 mL | 0.8693 mL | |
| 100 mM | 0.0278 mL | 0.1391 mL | 0.2782 mL | 0.6954 mL |
Glucagon receptor antagonist-3 Related Classifications
HY-50159 Related Classifications
Powered by Bioz